Lakefront Biotherapeutics American Depositary Shares
LKFT
41 hedge funds and large institutions have $453M invested in Lakefront Biotherapeutics American Depositary Shares in 2015 Q2 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.44% more ownership
Funds ownership: 0% → 13.44% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$206M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$58.4M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$40.6M |
| 4 |
DM
Deerfield Management
New York
|
+$34.1M |
| 5 |
O
OrbiMed
New York
|
+$27.2M |
Top Sellers
LKFT Hedge Fund Activity: Q2 2015 in Review
41 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2015, worth a combined $453M.
Buyers outnumbered sellers: 41 funds opened new LKFT positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $206M.
- 41 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $453M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2015.
- 41 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2015 and 0 closed out, a net change of +41 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2015 was Fidelity Investments, an estimated $206M added.
Based on aggregated 13F filings for Q2 2015.